Sat, Jan 31, 2015, 12:58 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

factman777 35 posts  |  Last Activity: 10 hours ago Member since: Oct 10, 2012
  • Vote who will win the Super Bowl

    Thumbs up = Seattle Seahawks
    Thumbs down = New England Patriots

    For the record (since I cannot vote) I am picking the Seahawks but I am rooting for an OT game.

    Have a great weekend,
    - FactMan777

    Sentiment: Strong Buy

  • Jan 22, 2015 - InVivo announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial. FactMan: very significant since this took only 13 days since enrollment was reopened and it is now very likely ongoing pilot study will be completed in 2015.
    Jan 29, 2015 - InVivo announces $12 Million Registered Direct Offering. FactMan: I believe the price of $1.50 was negotiated weeks ago. Management surely didn’t know the price of the stock was going to be over $2.00 on Jan 28, 2015. With the $1.4375 warrant exercise that will raise an additional $10 million they should be funded for all of 2015, 2016 and 2017.

    So to summarize, in the past year InVivo Therapeutics has:

    -built a solid highly-experienced leadership team.
    -received a patent covering Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells.
    -developed an outstanding relationship with the FDA which is so very important for a small bio-tech company.
    -opened 6 Clinical Study Sites for Neuro-Spinal Scaffold and received FDA approval to open up to 20 sites.
    -enrolled the first patient with this patient showing “unexpected gains”.
    -significantly reduced the timelines for the current 5 patient pilot study.
    -completed the enrollment of the 2nd patient in only 13 days.
    -funded the company out to 2018 so a partner will not be needed going forward. As per mikerconfer: “Shares issued in Secondaries can always be bought back but a development and marketing partnership is the gift that keeps on picking your pocket forever.” InVivo now has solid control of their financial future which will better serve them in all future negotiations.

    Final management grade = A+

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • Oct 29, 2014 - InVivo receives FDA Approval to Broaden Inclusion Criteria and Add 14 Additional Sites (20 Total) for Ongoing Pilot Trial.
    Nov 5, 2014 – business update: InVivo has made substantial progress on all fronts during the third quarter and have continued to build upon that momentum in the weeks since. In that timeframe, we enrolled our first subject in our first-in-human pilot trial, expanded the number of potential clinical sites, broadened subject eligibility criteria, increased our communications outreach through scientific, medical, and investor conferences, and significantly strengthened our intellectual property portfolio.
    Nov 11, 2014 - InVivo announces Appointment of Ann Merrifield to Its Board of Directors
    Nov 21, 2-14 - InVivo announces Oregon Health & Science University as the Fifth Clinical Trial Site for Neuro-Spinal Scaffold
    Nov 25, 2014 - InVivo announces University of Pittsburgh Medical Center Presbyterian as the Sixth Clinical Trial Site for Neuro-Spinal Scaffold
    Dec 16, 2014 - InVivo announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial. FactMan: very significant since it clearly confirms the outstanding relationship the company has developed with the FDA while also significantly shortening the timeframe of the ongoing pilot trial.
    Jan 9, 2015 - InVivo announces Reopening of Enrollment for Ongoing Pilot Trial and no reported serious safety events in the study’s first subject
    .Jan 21, 2015 - InVivo reports three-Month Update of First Acute Spinal Cord Injury Subject Implanted with Neuro-Spinal Scaffold - Motor, Sensory, Bowel, and Bladder Function Improvement with No Reported Serious Adverse Events. Dr. Theodore said, “I am very pleased with the first subject’s progress since the scaffold was implanted. In my experience, this degree of sensory and motor improvement is unexpected.” FactMan: it doesn’t get much better than this!!!

    -continued…

    Sentiment: Strong Buy

  • Jun 24, 2014 - InVivo announces New Responsibilities for Senior Management Team Members. William D’Agostino, PE has been appointed Senior Vice President, Operations. Kristin Neff has been appointed Vice President, Clinical Operations & Project Management. Lisa Crockett has been appointed Vice President, Regulatory Affairs & Reimbursement Planning. FactMan: it is my understanding that Kristen Neff is a tireless worker and is responsible for getting the clinical sites ready to enroll patients.
    Jun 26, 2014 – InVivo announces Barrow Neurological Institute As Third Clinical Trial Site for Neuro-Spinal Scaffold. BNI at St. Joseph's Hospital and Medical Center is the largest dedicated neurosurgical center in the world.
    July 1, 2014 - InVivo appoints Christopher McNulty as Vice President, Business Development & Investor Relations
    Aug 6, 2014 – business update: InVivo announces that our new highly-experienced leadership team represents the best people to drive the development of our two major products: the Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold plus stem cells programs. These two major assets form the foundational core of our newly focused mission, which is to lead as the experts in the field of spinal cord injury.
    Aug 11, 2014 - InVivo receives Notice of Allowance on Patent Covering Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells.
    Sep 29, 2014 - InVivo announces Appointment of Daniel R. Marshak, PhD to Its Board of Directors.
    Oct 15, 2014 – InVivo announced that the first subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Barrow Neurological Institute.
    Oct 20, 2014 - InVivo announces Barnes-Jewish Hospital at Washington University as its fourth Clinical Trial Site for Neuro-Spinal Scaffold.

    -continued…

    Sentiment: Strong Buy

  • A wise man once told me...

    If you are investing in real estate the 3 most important things to consider are: Location, Location and Location. And if you are investing in a company the 3 most important things to consider are: Management, Management and Management.

    So let’s review how the current management team at InVivo has performed since Jan 2014 when the current CEO Mark Perrin was appointed.

    Jan 6, 2014 – Mark Perrin appointed CEO.
    Jan 29, 2014 – Thomas R. Ulrich MD appointed Chief Scientific Officer.
    Mar 17, 2014 – Tamara L Joseph appointed Senior VP, General Counsel and Chief Compliance Officer.
    Mar 17, 2014 - business update: One clinical site has now received IRB approval and finalized its contract and a second site is nearing completion.. Additional sites are progressing through this process.
    Apr 28, 2014 – InVivo Initiates First Clinical Trial of Neuro-Spinal Scaffold.
    May 5, 2014 – announces proposed public offering at $1.15. FactMan: Even though this was a very unpopular and difficult decision by management, it was the right decision at the time to raise money in a difficult market with the former disgruntled CEO dumping shares on the market. This increased the cash runway out to Nov 2015.
    May 12, 2014 – business update: patient enrollment will be opened by the end of May.
    May 14, 2014 – InVivo announces Its Second Clinical Study Site for Neuro-Spinal Scaffold, the Carolinas Medical Center in Charlotte, NC.
    Jun 23, 2014 – InVivo announces realignment of R&D strategy. FactMan: Another difficult correct decision by management to eliminate the hydrogel drug delivery program and focus even stronger on the company’s core mission: developing meaningful treatments for spinal cord injury. The company also announced that it is making a reduction in force (RIF) of 14 employees, or 28% of its workforce which will result in annualized savings of $3 million and extend the cash runway through March 2016.

    -continued…

    Sentiment: Strong Buy

  • factman777 factman777 Jan 29, 2015 12:15 PM Flag

    My understanding (from talking with IR recently) is that the Mandatory Exercise you are quoting is not about the 7 million $1.4375 warrants. I was told by IR that the 7 million $1.4375 warrants are NOT callable.

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • Reply to

    Becker Spine Review

    by agentofinfluence Jan 28, 2015 3:43 PM
    factman777 factman777 Jan 28, 2015 5:44 PM Flag

    Good Post. Welcome aboard to the the best Yahoo Message Board IMHO.

    -FactMan777

    Sentiment: Strong Buy

  • Reply to

    New guy on block ...

    by smithlewis89 Jan 27, 2015 9:26 PM
    factman777 factman777 Jan 27, 2015 9:33 PM Flag

    Google: Robert S. Langer

    Sentiment: Strong Buy

  • Reply to

    Patient #2

    by at.slater Jan 27, 2015 7:22 PM
    factman777 factman777 Jan 27, 2015 7:42 PM Flag

    InVivo Therapeutics Holdings Corp. January 22, 2015 8:00 AM

    InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial

    InVivo Therapeutics Holdings Corp. (NVIV) today announced that a second subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Carolinas Medical Center, part of the Carolinas HealthCare System in Charlotte, NC. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.

    Dr. Domagoj Coric, Chief of Neurosurgery at Carolinas Medical Center, together with Dr. William Bockenek, Chief Medical Officer of Carolinas Rehabilitation, are Co-Principal Investigators at this site. Dr. Coric and his partner Dr. John Ziewacz, both of the Carolina Neurosurgery and Spine Associates, performed the second-ever Neuro-Spinal Scaffold implant into an acute spinal cord injury patient. Dr. Coric commented, “This subject sustained a severe, multi-trauma injury that required my team to wait two days for the subject to stabilize medically before proceeding with the concurrent spinal stabilization and implantation surgery. The implantation procedure was a success, and I look forward to monitoring the subject’s progress.”

    Just the facts,
    FactMan777

    Sentiment: Strong Buy

  • The timing of enrolling patients is not under the company’s control and can significantly affect the company’s timelines. It took almost 4 months to enroll the first patient with 3 opened sites. InVivo reopened the enrollment for the second subject on Jan 9, 2015 and it took only 13 days for this enrollment to be completed. This is fantastic news and I would now consider the company to be ahead of schedule. It is now very likely InVivo will complete the ongoing pilot study in 2015 since concurrent enrollment of subjects three to five can begin in about two months. Also, there will probably be several more sites opened for enrollment going forward since as of Oct 29, 2014 the FDA expanded the number of allowable clinical sites from 6 to 20.

    Unbelievable that this stock is still under $2.00 a share after these recent catalysts:

    -Statement from InVivo that the subject has progressed in three months from a complete AIA A injury to an incomplete AIS C injury with motor, sensory, bowel, and bladder function improvements.

    -Statement from Dr. Theodore (one of the top neurosurgeons in the world) that the degree of sensory and motor improvement is unexpected.

    -Actual videos of Jordan walking in a pool and crawling on the ground

    -Second patient enrolled in only 13 days

    I have to believe that this low share price will not last very long as more and more investors become aware of the major medical breakthrough that is unfolding before their very eyes.

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • factman777 factman777 Jan 22, 2015 4:09 PM Flag

    Looks like Frank is not so dumb after all. He knows this stock is going much higher so apparently he is waiting for higher prices.

    SC 13D - 11/01/2010 – ownership of 15,932,584 shares
    SC 13D/A - 03/04/2014 – Amendment #1 - owns 9,809,908 (12.5% of shares)
    SC 13D/A –05/15/2014 – Amendment #2 - owns 9,000,320 (9.7% of shares)
    SC 13D/A - 08/29/2014 – Amendment #3 - owns 6,945,699 (7.4% of shares)
    SC 13D/A –09/24/2014 – Amendment #4 - owns 6,001,260 (6.4% of shares)
    SC 13D/A –01/16/2015 – Amendment #5 - owns 5,013,260 (5.3% of shares)

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • Reply to

    Are we talkng 4MIL shares today?

    by alexsissy Jan 21, 2015 9:42 AM
    factman777 factman777 Jan 21, 2015 4:24 PM Flag

    You nailed it. Volume = 4,072,948.

    Just the facts,
    FactMan777

    Sentiment: Strong Buy

  • Reply to

    Coming

    by tonto.warrior Jan 16, 2015 5:29 PM
    factman777 factman777 Jan 16, 2015 11:12 PM Flag

    English Translation...

    By Groundhog Day, Monday February 2, 2015, many NVIV shareholder will be happy.

    Folks, that 9 trading days..

    -Factman777

    Sentiment: Strong Buy

  • Reply to

    Warrants details

    by hareeshd Jan 16, 2015 12:57 PM
    factman777 factman777 Jan 16, 2015 1:45 PM Flag

    From the original prospectus...

    The warrants to be issued in this offering will not be listed for trading on any stock exchange, the Over the Counter Bulletin Board or OTC Markets, Inc. There is no established public trading market for the warrants being offered in this offering and we do not expect a market to develop.

    The initial exercise price per share of common stock purchasable upon exercise of the warrants is $1.4375 per share.

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • Reply to

    Nice Finish on Strong volume

    by alexsissy Jan 6, 2015 4:10 PM
    factman777 factman777 Jan 6, 2015 4:47 PM Flag

    You can try this free web site:

    http://quotes.freerealtime.com/dl/frt/S

    just enter NVIV towards the upper right and use the pull-down menu to select: RT Quote or Times&Sales

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • Sure would like to know if this is Frank Reynolds selling.

    He has not filed a Schedule 13D/A since Sep 24, 2014.

    SC 13D - 11/01/2010 – ownership of 15,932,584 shares
    SC 13D/A - 03/04/2014 – Amendment #1 - owns 9,809,908 (12.5% of shares)
    SC 13D/A –05/15/2014 – Amendment #2 - owns 9,000,320 (9.7% of shares)
    SC 13D/A - 08/29/2014 – Amendment #3 - owns 6,945,699 (7.4% of shares)
    SC 13D/A –09/24/2014 – Amendment #4 - owns 6,001,260 (6.4% of shares)

    I am one to believe that once he is done selling it will be like taking the lid off the share price. Sure the stock got way ahead of itself at $6.00 when Frank was pumping with his omission lies. But no way should NVIV be at $1.40 with a ton of potential catalysts ahead of us in 2015.

    -FactMan777

    Sentiment: Strong Buy

  • I also want to thank all the NVIV posters for making this message board one of the most intelligent and enjoyable message boards to read. As you know, in the bio-tech world, things often move slowly and it’s nice to have a daily good read to look forward to each day.

    mikerconfer
    alleg180
    alexsissy
    andersonstephen494
    andymann7464
    aretxen
    awesomestranger
    babuyayaya
    bstnbaked
    bubbajones6689
    buckboard221
    buy_n_hold_2001
    byecell
    chaines1443
    chiefbilbatt4
    cmcfar99
    craig33157
    cutiger1980
    cynicoptimist
    crystalmanning5757
    dirkjams
    djalexi22
    dogsscrewbrokerss
    duckbillthrill
    englishrose730
    envy_vo
    fagenbecker
    flsh56
    gamuril
    gary_anderson_3dprintingstocks
    gemineyedream
    gusthegator
    imamisanthrope
    imnorockefeller
    inquietudo1
    jmnotechie
    johnnykabuki_xxxxx
    jssflash
    junkdna50
    kcandme47
    lion_guru_1
    lookingfortink
    ma38rk
    magpi10021
    marcingt46
    mastiffsforlife
    microcapresearch_com
    mikewatkins85
    mix.jack
    mmccormack1279
    mofisher22
    moneygrubber13
    mycouchpullsoutbutidont1
    nflfantasychris
    pistol1p
    regener8ve
    richs375
    rmccabe7
    rosesny1
    rwrop
    siadatana
    smuf1
    southshoretrader
    stockman188
    tbone8973
    tonto.warrior
    tsyoung1111
    voisybay
    valueguyhp2002
    whiskeysausage
    wilderguide
    ylb2
    yzzycz

    Looking forward to a very exciting 2015,
    -FactMan777

    Sentiment: Strong Buy

  • Reply to

    Reminder

    by tonto.warrior Dec 30, 2014 11:36 AM
    factman777 factman777 Dec 30, 2014 2:39 PM Flag

    No firewater for tonto in 2015. Must not miss any smoke signals.

    For those wishing to communicate with tonto…

    -select an area to set up a smoke signal system that is visible from a great distance
    -virtually all solid materials emit a white "smoke" when first heated which is mostly moisture. As a material dries out the color of the smoke changes. Wood materials produce a tan or brown color. The addition of other materials such as damp leaves or grass encouraged thick smoke.
    -use blanket to prevent smoke from rising. When a lot of smoke had been imprisoned beneath it, the blanket is raised so as to let it escape
    -blanket then lowered, held, and raised again causing new puff or cloud
    -these puffs of smoke rise and according to their number, the message being sent is varied.

    -FactMan777

    Sentiment: Strong Buy

  • It’s nice to see NVIV close at its highest price since May 6, 2014. The morning of May 6 was when the secondary offering priced at $1.15 was announced and the stock closed that day at $1.15 with a volume of 5,252,800 shares traded.

    It sure has been a rocky road to get to where we are today but I believe with the current management team the best is yet to come in 2015.

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • Reply to

    warrants could bring in extra cash

    by dogsscrewbrokerss Dec 26, 2014 7:01 PM
    factman777 factman777 Dec 26, 2014 8:08 PM Flag

    For those who missed my post from Dec. 18, 2014...

    InVivo currently has 7,000,000 warrants outstanding with a conversion price of $1.43. I have to believe that InVivo share price will easily rise above $1.43 in the next 6 months. So here is the math…

    Cash as of Jun 30, 2014 = $20,850,000
    Cash as of Sep 30, 2014 = $17,634,000
    Cash burn for 3rd quarter = 20,850,000 - 17,634,000 = $3,216,000
    Monthly cash burn for 3rd quarter = 3,216,000 / 3 = $1,072,000

    7 million warrant conversion: 7,000,000 x 1.43 = $10,010,893
    Total Cash = 17,634,000 + 10,010,893 = $27,644,893
    Cash runway = 27,644,893 / 1,072,000 = 25.79 months of cash

    Oct 1, 2014 + 25.79 months has the cash runway out to late Nov 2016.

    With the recent FDA approval to expedite the safety study, the company should be able to easily finish this 5 patient safety study and kick off a scaffold+stems cells study for acute SCI patients and then onto the holy grail (scaffold+stem cells for chronic SCI patients). They will have no trouble signing up chronic SCI patients. In fact, there will probably be a waiting list of patients to have the scaffold+stem cells implanted.

    Also, with the obvious solid relationship that InVivo has developed with the FDA, I think that starting both studies (scaffold+stem cells for acute and chronic SCI patients) concurrently is now a real possibility.

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

NVIV
1.96-0.03(-1.51%)Jan 30 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Boot Barn Holdings, Inc.
NYSEFri, Jan 30, 2015 4:02 PM EST
Visa Inc.
NYSEFri, Jan 30, 2015 4:00 PM EST